SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Hahn BH. Targeted therapies in systemic lupus erythematosus: successes, failures and future. Ann Rheum Dis 2011; 70 Suppl I: i646.
  • 2
    Ren K, Purdue PE, Burton L, Quan LD, Fehringer EV, Thiele GM. Early detection and treatment of wear particle-induced inflammation and bone loss in a mouse calvarial osteolysis model using HPMA copolymer conjugates. Mol Pharm 2011; 8: 104351.
  • 3
    Liu XM, Quan LD, Tian J, Alnouti Y, Fu K, Thiele GM, et al. Synthesis and evaluation of a well-defined HPMA copolymer-dexamethasone conjugate for effective treatment of rheumatoid arthritis. Pharm Res 2008; 25: 29109.
  • 4
    Quan LD, Purdue PE, Liu XM, Boska MD, Lele SM, Thiele GM, et al. Development of a macromolecular prodrug for the treatment of inflammatory arthritis: mechanisms involved in arthrotropism and sustained therapeutic efficacy. Arthritis Res Ther 2010; 12: R170.
  • 5
    Omelyanenko V, Kopeckova P, Gentry C, Kopecek J. Targetable HPMA copolymer-adriamycin conjugates: recognition, internalization, and subcellular fate. J Control Release 1998; 53: 2537.
  • 6
    Lai JT, Filla D, Shea R. Functional polymers from novel carboxyl-terminated trithiocarbonates as highly efficient RAFT agents. Macromolecules 2002; 35: 67546.
  • 7
    Bynote KK, Hackenberg JM, Korach KS, Lubahn DB, Lane PH, Gould KA. Estrogen receptor-α deficiency attenuates autoimmune disease in (NZB × NZW)F1 mice. Genes Immun 2008; 9: 13752.
  • 8
    Kielian T, Syed MM, Liu S, Phulwani NK, Phillips N, Wagoner G, et al. The synthetic peroxisome proliferator-activated receptor-α agonist ciglitazone attenuates neuroinflammation and accelerates encapsulation in bacterial brain abscesses. J Immunol 2008; 180: 500416.
  • 9
    Manolides AS, Cullen DM, Akhter MP. Effects of glucocorticoid treatment on bone strength. J Bone Miner Metab 2010; 28: 5329.
  • 10
    Steward MW, Hay FC. Changes in immunoglobulin class and subclass of anti-DNA antibodies with increasing age in N/ZBW F1 hybrid mice. Clin Exp Immunol 1976; 26: 36370.
  • 11
    Sugisaki T, Takase S. Composition of immune deposits present in glomeruli of NZB/W F1 mice. Clin Immunol Immunopathol 1991; 61: 296308.
  • 12
    Butler WT, Rossen RD. Effects of corticosteroids on immunity in man. I. Decreased serum IgG concentration caused by 3 or 5 days of high doses of methylprednisolone. J Clin Invest 1973; 52: 262940.
  • 13
    Settipane GA, Pudupakkam RK, McGowan JH. Corticosteroid effect on immunoglobulins. J Allergy Clin Immunol 1978; 62: 1626.
  • 14
    Benigni A, Caroli C, Longaretti L, Gagliardini E, Zoja C, Galbusera M, et al. Involvement of renal tubular Toll-like receptor 9 in the development of tubulointerstitial injury in systemic lupus. Arthritis Rheum 2007; 56: 156978.
  • 15
    Ferraccioli G, Romano G. Renal interstitial cells, proteinuria and progression of lupus nephritis: new frontiers for old factors. Lupus 2008; 17: 53340.
  • 16
    Ronda N, Cravedi P, Benozzi L, Lunghi P, Bonati A, Allegri L, et al. Early proinflammatory activation of renal tubular cells by normal and pathologic IgG. Nephron Exp Nephrol 2005; 100: e7784.
  • 17
    Yung S, Tsang RC, Sun Y, Leung JK, Chan TM. Effect of human anti-DNA antibodies on proximal renal tubular epithelial cell cytokine expression: implications on tubulointerstitial inflammation in lupus nephritis. J Am Soc Nephrol 2005; 16: 328194.
  • 18
    Boswell RN, Yard BA, Schrama E, van Es LA, Daha MR, van der Woude FJ. Interleukin 6 production by human proximal tubular epithelial cells in vitro: analysis of the effects of interleukin-1α (IL-1α) and other cytokines. Nephrol Dial Transplant 1994; 9: 599606.
  • 19
    Cunningham PN, Holers VM, Alexander JJ, Guthridge JM, Carroll MC, Quigg RJ. Complement is activated in kidney by endotoxin but does not cause the ensuing acute renal failure. Kidney Int 2000; 58: 15807.
  • 20
    Wang D, Miller SC, Liu XM, Anderson B, Wang XS, Goldring SR. Novel dexamethasone-HPMA copolymer conjugate and its potential application in treatment of rheumatoid arthritis. Arthritis Res Ther 2007; 9: R2.
  • 21
    Macanovic M, Sinicropi D, Shak S, Baughman S, Thiru S, Lachmann PJ. The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice: studies with recombinant murine DNase and with dexamethasone. Clin Exp Immunol 1996; 106: 24352.
  • 22
    Perysinaki GS, Moysiadis DK, Bertsias G, Giannopoulou I, Kyriacou K, Nakopoulou L, et al. Podocyte main slit diaphragm proteins, nephrin and podocin, are affected at early stages of lupus nephritis and correlate with disease histology. Lupus 2011; 20: 78191.
  • 23
    Kelley VE, Cavallo T. An ultrastructural study of the glomerular slit diaphragm in New Zealand black/white mice. Lab Invest 1976; 35: 21320.
  • 24
    Howie JB, Helyer BJ. The immunology and pathology of NZB mice. Adv Immunol 1968; 9: 21566.
  • 25
    Choi HS, Liu W, Misra P, Tanaka E, Zimmer JP, Itty Ipe B, et al. Renal clearance of quantum dots. Nat Biotechnol 2007; 25: 116570.
  • 26
    Kamada H, Tsutsumi Y, Sato-Kamada K, Yamamoto Y, Yoshioka Y, Okamoto T, et al. Synthesis of a poly(vinylpyrrolidone- co-dimethyl maleic anhydride) co-polymer and its application for renal drug targeting. Nat Biotechnol 2003; 21: 399404.
  • 27
    Kodaira H, Tsutsumi Y, Yoshioka Y, Kamada H, Kaneda Y, Yamamoto Y, et al. The targeting of anionized polyvinylpyrrolidone to the renal system. Biomaterials 2004; 25: 430915.
  • 28
    Yuan ZX, Sun X, Gong T, Ding H, Fu Y, Zhang ZR. Randomly 50% N-acetylated low molecular weight chitosan as a novel renal targeting carrier. J Drug Target 2007; 15: 26978.
  • 29
    Yuan ZX, Zhang ZR, Zhu D, Sun X, Gong T, Liu J, et al. Specific renal uptake of randomly 50% N-acetylated low molecular weight chitosan. Mol Pharm 2009; 6: 30514.
  • 30
    Quan LD, Yuan F, Liu XM, Huang JG, Alnouti Y, Wang D. Pharmacokinetic and biodistribution studies of N-(2-hydroxypropyl)methacrylamide copolymer-dexamethasone conjugates in adjuvant-induced arthritis rat model. Mol Pharm 2010; 7: 10419.